AKT1 and neoplasm: RUNX3-overexpression synergises with inhibition of protein kinase B (Akt) to promote additional TCM differentiation in CAR-T cells, which produces robust and improved anti-tumour responses in pancreatic ductal adenocarcinoma patient-derived xenograft tumour models (173).